Effect of gastric distension with concurrent small intestinal saline or glucose infusion on incretin hormone secretion in healthy individuals: A randomized, controlled, crossover study

Diabetes Obes Metab. 2023 Jul;25(7):1849-1854. doi: 10.1111/dom.15042. Epub 2023 Mar 17.

Abstract

Aim: To evaluate the effect of gastric distension, induced using a gastric 'barostat', on the secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in the presence and absence of small intestinal nutrients in healthy individuals.

Materials and methods: Eight healthy participants (two females, six males, mean age 69.3 ± 1.2 years, body mass index 23.5 ± 0.8 kg/m2 ) were each studied on four occasions when they received an intraduodenal infusion of either (i) 0.9% saline or (ii) glucose delivered at a rate of 3 kcal/min both with, and without, an intragastric balloon with the pressure set to 8 mmHg above the intragastric minimum distending pressure.

Results: Following intraduodenal saline or glucose infusion, there was no difference in plasma GLP-1 with or without gastric distension (P = 1.00 for both saline and glucose infusions). There was also no difference in plasma GIP with or without gastric distension (P = 1.00 for saline infusion and P = .99 for glucose infusion).

Conclusions: Gastric distension, either alone or during small intestinal glucose exposure, does not stimulate incretin hormone secretion significantly in healthy humans.

Keywords: barostat; gastric distension; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; incretin; intragastric balloon.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Blood Glucose
  • Cross-Over Studies
  • Female
  • Gastric Balloon*
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide 1
  • Glucose*
  • Humans
  • Incretins
  • Insulin
  • Male
  • Saline Solution

Substances

  • Glucose
  • Incretins
  • Blood Glucose
  • Saline Solution
  • Gastric Inhibitory Polypeptide
  • Glucagon-Like Peptide 1
  • Insulin